Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.
Analysts polled by Capital IQ expected $0.66.
Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.
Analysts polled by Capital IQ expected $4.13 billion.
The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.
Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.
Shares of the company were up 3.9% in recent Wednesday premarket activity.
Price: 19.50, Change: +0.73, Percent Change: +3.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。